BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10381754)

  • 1. Inhibition of phosphodiesterase III with milrinone increases renin secretion in human subjects.
    Chiu YJ; Hu SH; Reid IA
    J Pharmacol Exp Ther; 1999 Jul; 290(1):16-9. PubMed ID: 10381754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. cGMP stimulates renin secretion in vivo by inhibiting phosphodiesterase-3.
    Beierwaltes WH
    Am J Physiol Renal Physiol; 2006 Jun; 290(6):F1376-81. PubMed ID: 16449359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cyclic GMP-inhibitable phosphodiesterase and nitric oxide in the beta adrenoceptor control of renin secretion.
    Chiu T; Reid IA
    J Pharmacol Exp Ther; 1996 Aug; 278(2):793-9. PubMed ID: 8768733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram.
    Chiu N; Park I; Reid IA
    J Pharmacol Exp Ther; 1996 Mar; 276(3):1073-7. PubMed ID: 8786537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes of post-ischemic hepatic microcirculation improved by a pre-treatment of phosphodiesterase-3 inhibitor, milrinone.
    Kume M; Banafsche R; Yamamoto Y; Yamaoka Y; Nobiling R; Gebhard MM; Klar E
    J Surg Res; 2006 Dec; 136(2):209-18. PubMed ID: 17045613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphodiesterase III inhibition affects platelet-monocyte aggregate formation depending on the axis of stimulation.
    Horn NA; Anastase DM; Hecker KE; Baumert JH; Scheffer GJ; Rossaint R
    J Cardiothorac Vasc Anesth; 2006 Apr; 20(2):162-6. PubMed ID: 16616654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation.
    Thomas RE; Armstrong DT; Gilchrist RB
    Dev Biol; 2002 Apr; 244(2):215-25. PubMed ID: 11944932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
    Birk S; Edvinsson L; Olesen J; Kruuse C
    Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of erectile response and cAMP accumulation by combination of prostaglandin E1 and rolipram, a selective inhibitor of the type 4 phosphodiesterase (PDE 4).
    Bivalacqua TJ; Champion HC; Rajasekaran M; Sikka SC; Kadowitz PJ; Doherty PC; Hellstrom WJ
    J Urol; 1999 Nov; 162(5):1848-55. PubMed ID: 10524946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic type IV phosphodiesterase inhibition protects glomerular filtration rate and renal and mesenteric blood flow in a zymosan-induced model of multiple organ dysfunction syndrome treated with norepinephrine.
    Thomas NJ; Carcillo JA; Herzer WA; Mi Z; Jackson EK
    J Pharmacol Exp Ther; 2001 Jan; 296(1):168-74. PubMed ID: 11123377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential regulation of human platelet responses by cGMP inhibited and stimulated cAMP phosphodiesterases.
    Manns JM; Brenna KJ; Colman RW; Sheth SB
    Thromb Haemost; 2002 May; 87(5):873-9. PubMed ID: 12038792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of sildenafil on renin secretion in human subjects.
    Chiu YJ; Reid IA
    Exp Biol Med (Maywood); 2002 Sep; 227(8):620-5. PubMed ID: 12192104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effects of phosphodiesterase III inhibitors on glucose metabolism and insulin sensitivity.
    Yang G; Li L
    J Chin Med Assoc; 2003 Apr; 66(4):210-6. PubMed ID: 12854872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of milrinone administrated before weaning from cardiopulmonary bypass in adult cardiac surgery].
    Hibino N; Tomino T; Satoh H; Hamawaki M; Imura M; Suzuki T; Inukai M
    Kyobu Geka; 2000 Nov; 53(12):1019-23. PubMed ID: 11079307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuronal nitric oxide synthase supports Renin release during sodium restriction through inhibition of phosphodiesterase 3.
    Sällström J; Jensen BL; Skøtt O; Gao X; Persson AE
    Am J Hypertens; 2010 Nov; 23(11):1241-6. PubMed ID: 20651700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How to use PDE III inhibitors].
    Goto Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():49-56. PubMed ID: 17571365
    [No Abstract]   [Full Text] [Related]  

  • 19. [Phosphodiesterase III inhibitor--characteristics, mechanisms of action, pharmacokinetics, indications, contraindications, clinical trials, and side effects].
    Sato N
    Nihon Rinsho; 2007 May; 65 Suppl 5():43-8. PubMed ID: 17571364
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases.
    Weiss HR; Gong GX; Straznicka M; Yan L; Tse J; Scholz PM
    Can J Physiol Pharmacol; 1999 Jun; 77(6):422-31. PubMed ID: 10537228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.